R & S Solutions Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: R & S Solutions Pharmaceutical Import Records from India — 3 Products, $1.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

R & S Solutions — Pharmaceutical Importer Profile (2026) | 3 Products, $1.3M Trade | TransData Nexus

R & S Solutions

Pharmaceutical Importer · United States · Gastrointestinal Focus · $1.3M Total Trade · DGFT Verified

R & S Solutions is a pharmaceutical importer based in United States with a total trade value of $1.3M across 3 products in 3 therapeutic categories. Based on 38 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. R & S Solutions sources from 4 verified Indian suppliers, with Orbion Pharmaceuticals Private Limited accounting for 87.6% of imports.

R & S Solutions — Import Portfolio & Supplier Network

R & S Solutions import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to R & S Solutions?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Orbion Pharmaceuticals Private Limited	$6.7M	231	87.6%
Recipharm Pharmaservices Private Limited	$482.1K	10	6.3%
Unichem Laboratories Limited

What Formulations Does R & S Solutions Import?

Formulation	Value	Ships
Modafinil tablets,USP 200MG 30ct	$600.0K	12
Modafinil tablets,USP 100MG 30ct	$600.0K	12
Naratriptan tablets USP 2.5MG 9s usa Pack: 9 tabs / blister (rodtep entry no.3081)	$397.4K	9
Sumatriptan tablets 50MG USP Pack:9 TAB	$353.6K	16
Loperamide hydrochloride CAPS 2 MG	$282.7K	6
Sumatriptan tablets USP 25MG 9ct	$212.4K	16
Tramadol hydrochloride tablets USP 50MG	$200.0K	4
Loperamide hcl capsules USP 2MG hdpe	$174.9K	4
Colesevelam hci tablets 625 MG 180/bt Pack : 180 TAB	$172.7K	4
Colesevelam hcl tablets 625MG,Pack:180 TAB	$172.0K	4
Sumatriptan tablets, USP 100MG 9ct	$165.5K	4
Lopermide hydrochloride CAPS 2 MG	$150.0K	3
Dofetilide capsules 250mcg 60ct	$143.6K	3
Ropinirole tablets 0.25MG 100 ct	$108.5K	4
Carbamazepine tablets USP 200MG hdpe 100s Pack:100 tabs (rodtep entry no. 3066)	$100.0K	2

R & S Solutions imports 119 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Loperamide	Gastrointestinal	$571.0K	14	0.8%	11
2	Terbinafine	Antifungals	$362.6K	16	1.3%	18
3	Theophylline	Respiratory	$317.2K	8	2.0%	11

R & S Solutions imports 3 pharmaceutical products across 3 categories into United States totaling $1.3M.

R & S Solutions — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

R & S Solutions is a pharmaceutical importer and buyer based in the United States, specializing in the procurement of finished pharmaceutical formulations from international suppliers. Headquartered at 96 American Drive, Suite 100A, Jackson, Tennessee 38301, the company has been operational since at least March 2014, as evidenced by import records from that period. R & S Solutions plays a significant role in the U.S. pharmaceutical distribution network by sourcing a diverse range of pharmaceutical products from global manufacturers, ensuring a steady supply of medications to meet domestic demand.

2Distribution Network

While specific details about R & S Solutions' warehouse locations and logistics capabilities are not publicly disclosed, the company's import activities indicate a well-established distribution network. The import data reveals shipments arriving at major U.S. ports, including Charleston, South Carolina, and Savannah, Georgia, suggesting a strategic approach to logistics and distribution. This distribution strategy likely enables R & S Solutions to efficiently serve various regions across the United States.

3Industry Role

R & S Solutions operates as a pharmaceutical importer and buyer, sourcing finished pharmaceutical formulations from international suppliers, particularly from India. The company's role is pivotal in the U.S. pharmaceutical supply chain, acting as an intermediary between foreign manufacturers and domestic healthcare providers. By importing a diverse array of pharmaceutical products, R & S Solutions ensures the availability of essential medications, contributing to the overall efficiency and reliability of the U.S. pharmaceutical distribution system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — R & S Solutions

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

R & S Solutions demonstrates a high degree of supplier concentration, with a significant portion of its imports sourced from a limited number of suppliers. The top four verified Indian suppliers account for approximately 99.9% of the total import value, with ORBION PHARMACEUTICALS PRIVATE LIMITED alone contributing 87.6% of the total shipments. This concentrated sourcing strategy may offer benefits such as streamlined logistics and potentially favorable pricing agreements. However, it also introduces risks related to supply chain disruptions, as any issues with these key suppliers could significantly impact R & S Solutions' ability to meet domestic demand.

2Supply Chain Resilience

The resilience of R & S Solutions' supply chain is closely tied to the stability and reliability of its primary suppliers. The company's heavy reliance on a few key suppliers, particularly ORBION PHARMACEUTICALS PRIVATE LIMITED, suggests that any disruptions in these suppliers' operations could have a substantial impact on R & S Solutions' ability to maintain a consistent supply of pharmaceutical products. To enhance supply chain resilience, it would be prudent for R & S Solutions to diversify its supplier base and establish contingency plans to mitigate potential risks associated with supplier dependency.

Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations to ensure that imported drugs meet safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines requirements for drug approval, labeling, and manufacturing practices. For Indian generics to be marketed in the U.S., they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the brand-name counterpart.

2Import Licensing & GMP

Importers like R & S Solutions must comply with FDA regulations, including obtaining an Importer of Record (IOR) number and ensuring that imported pharmaceutical products are accompanied by appropriate documentation, such as Certificates of Analysis and Certificates of Good Manufacturing Practice (GMP). The FDA recognizes GMP certifications from reputable authorities, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications attest to the manufacturing standards of foreign suppliers, ensuring that imported drugs meet the FDA's quality requirements.

R & S Solutions — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

R & S Solutions focuses on importing pharmaceutical products across three therapeutic categories: gastrointestinal, antifungals, and respiratory. The top three products imported are Loperamide, Terbinafine, and Theophylline, which align with these therapeutic areas. This strategic focus suggests that R & S Solutions is responding to market demand for treatments in these categories, aiming to provide essential medications to address prevalent health conditions in the U.S.

2Sourcing Profile

R & S Solutions' sourcing strategy emphasizes the importation of generic drugs, particularly those manufactured in India. The company's preference for finished pharmaceutical formulations indicates a focus on ready-to-market products, facilitating quicker distribution and availability. India's established pharmaceutical manufacturing industry, known for its adherence to international quality standards, makes it a favorable sourcing destination for R & S Solutions.

3Market Positioning

Based on its product mix, R & S Solutions serves a segment of the U.S. market that includes retail pharmacies, hospitals, and healthcare facilities requiring a steady supply of generic medications. By focusing on essential therapeutic areas such as gastrointestinal, antifungal, and respiratory treatments, the company positions itself as a reliable supplier catering to the diverse needs of the healthcare sector.

Seller's Guide — How to Become a Supplier to R & S Solutions

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with R & S Solutions, especially if they can offer products that align with the company's focus on gastrointestinal, antifungal, and respiratory medications. Suppliers that can demonstrate compliance with FDA regulations, provide competitive pricing, and ensure consistent product quality may find a receptive partner in R & S Solutions. Diversifying the supplier base could also enhance R & S Solutions' supply chain resilience and mitigate risks associated with over-reliance on a few key suppliers.

2Requirements & Qualifications

Indian exporters seeking to supply R & S Solutions and the U.S. market must obtain FDA approval for their products, which involves demonstrating bioequivalence through the ANDA process. Manufacturing facilities must adhere to recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, exporters must ensure that their products meet FDA labeling requirements, including providing information in English and complying with serialization mandates under the DSCSA.

3How to Approach

Frequently Asked Questions — R & S Solutions

What products does R & S Solutions import from India?

R & S Solutions imports 3 pharmaceutical products across 3 categories. Top imports: Loperamide ($571.0K), Terbinafine ($362.6K), Theophylline ($317.2K).

Who supplies pharmaceuticals to R & S Solutions from India?

R & S Solutions sources from 4 verified Indian suppliers. The primary supplier is Orbion Pharmaceuticals Private Limited (87.6% of imports, $6.7M).

What is R & S Solutions's total pharmaceutical import value?

R & S Solutions's total pharmaceutical import value from India is $1.3M, based on 38 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does R & S Solutions focus on?

R & S Solutions imports across 3 categories. The largest: Gastrointestinal (45.7%), Antifungals (29.0%), Respiratory (25.4%).

Get Full R & S Solutions Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.